CD274 and neoplasm: Anti-PD-L1 promoted tumor rejection in 50% of B16-F0 melanoma challenged mice (P = 0.031) and 50% of B16-F1 melanoma challenged mice (P = 0.031; Figures 4(a) and 4(b)).